Analysis of the latest market price of lorlatinib in 2023
As a powerful treatment tool for lung cancer, the price trend of Lorlatinib has always attracted much attention. Entering 2023 , the price of lorlatinib (lorlatinib) in China has been reduced due to its inclusion in medical insurance, but it still remains at a high level of 10,000 to 20,000 yuan, which is undoubtedly a considerable financial burden for many patients. To know the specific price after medical insurance reimbursement, patients need to go to the local hospital or pharmacy for consultation in person.
Looking at the international market, the price of lorlatinib (lorlatinib) varies significantly. In Türkiye, the price of original research drugs is relatively affordable, which is about 7,000 yuan when converted into RMB. However, in Hong Kong, China, the price of the same original drug has soared to about 30,000 yuan. Of course, there are more economical options on the market - generic drugs. At present, generic drugs have been launched in countries such as Laos and Bangladesh, with prices ranging from more than a thousand yuan to several thousand yuan. This undoubtedly provides new hope for patients who cannot afford the high prices of original drugs.
It needs to be emphasized that although generic drugs are basically the same as original drugs in terms of ingredients, they must be purchased through formal channels to ensure the quality and safety of the drugs. For those patients with limited budget, generic drugs may be a good choice, but it is best to seek professional medical advice before using them.
The high price of lorlatinib not only reflects the costs of developing and producing new drugs, but also reveals the economic pressures currently facing the healthcare system. In order to make this life-saving drug affordable for more patients, the government, medical institutions and pharmaceutical companies need to work together to promote the rationalization of drug prices through policy regulation and cooperative innovation, thereby improving the health level and quality of life of the entire society.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)